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ABSTRACT
Objectives To compare the effects of an intermediate 
molecular weight (MW) intra-articular hyaluronic acid 
(HA) with a low MW product on knee osteoarthritis (OA) 
symptoms. 
Methods Patients with symptomatic knee OA were 
enrolled inarandomised, controlled, double-blind, parallel-
group, non-inferiority trial with the possibility to shift to 
superiority. Patients were randomised to GO-ON(MW 
800–1500 kD, 25 mg/2.5 ml) or Hyalgan(MW 500–730 
kD, 20 mg/2 ml) injected at 3-weekly intervals. The 
primary outcome was 6-month change in the WOMAC 
pain subscale (0–100 mm). Sample size was calculated 
on a non-inferiority margin of 9 mm, lower than the 
minimum perceptible clinical improvement. Secondary 
endpoints included OARSI-OMERACT responder rates
Results The intention-to-treat (ITT) and per-protocol 
(PP) populations consisted of 217 and 209 patients and 
171 and 172 patients in the GO-ON and Hyalgan groups, 
respectively. ITT WOMAC pain of 47.5±1.0(SE) and 
48.8±1.0 mm decreased by 22.9±1.4 mm with GO-ON 
and 18.4±1.5 mm with Hyalgan after 6 months. The 
primary analysis was conducted in the PP population 
followed by the ITT population.Mean (95% CI) differences 
in WOMAC pain change were 5.2 (0.9 to 9.6)mm and 4.5 
(0.5 to 8.5)mm, respectively,favouring GO-ON, satisfying 
the claim for non-inferiority (lower limit>−9 mm) and 
for statistical superiority (95% CI all>0, p=0.021). 
Ahigher proportion of OARSI/OMERACT responders was 
observed with GO-ONthan with Hyalgan (73.3% vs58.4%, 
p=0.001). Both preparations were well tolerated.
Conclusions Treatment with 3-weekly injections of 
intermediate MW HA may be superior to low MW HA on 
knee OA symptoms over 6 months, with similar safety.
Hyaluronic acid (HA) is a glycosaminogly-
can constituent of synovial ﬂ uid and cartilage 
matrix in normal joints. In osteoarthritis, HA 
molecular weight (MW) and concentration are 
decreased. Exogenous HA is available as a vis-
cosupplementation device or a drug for intra-ar-
ticular use in the treatment of knee osteoarthritis 
symptoms.1 Different HA formulations are cur-
rently available worldwide: from the reference 
low MW preparation (range 500 000–730 000 
Daltons) to more recent intermediate MW (range 
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800 000–2 000 000) and even cross-linked, high 
MW formulations (average 6 000 000 Daltons) 
including hylans, non-animal-derived HA and 
others. However, the efﬁ cacy of HA in knee 
osteoarthritis is still debated, which is reﬂ ected 
in several meta-analyses;2–7 the majority suggest 
small to strong effects of HA,2–5 while a minority 
failed to show a greater effect than placebo.6 7 
Despite controversies, HA injections are recom-
mended by the current Osteoarthritis Research 
Society International (OARSI) guidelines and 
previous practice guidelines.8
While a more recent re-appraisal suggests that 
there is poor evidence of signiﬁ cant pain relief 
when the analysis is restricted to high-quality 
studies,9 one early meta-analysis4 suggested that 
the large heterogeneity between trials might be 
caused by the possible greater efﬁ cacy of high MW 
HA products. This was recently negated by a meta-
 analysis10 in which high MW, cross-linked HA was 
not signiﬁ cantly superior to lower MW prepara-
tions, but had a doubling frequency of post-injec-
tion joint ﬂ ares. In addition, HA was found to have 
longer-lasting pain control compared with intra-ar-
ticular corticosteroids, and the majority of trials has 
been performed with the low MW HA product.11
Low MW HA thus often remains the preferred 
option when using HA in knee osteoarthritis. 
However, there is a paucity of appropriately 
sized, high-quality trials comparing the effects 
of different MW preparations, with particular 
regard to potential differences between low and 
intermediate MW products, given the worse 
safety proﬁ le of high MW formulations.10 The 
present study was therefore designed to compare 
the effects of the reference low MW HA product 
(Hyalgan) with a well-characterised intermediate 
MW preparation (GO-ON) on knee osteoarthritis 
symptoms.
METHODS
Study design
This was a multicentre (50 orthopaedics and/
or rheumatology practice sites in France and 
Germany), prospective, randomised, double-blind, 
controlled, parallel-group trial, to compare the efﬁ -
cacy and safety of GO-ON with that of Hyalgan 
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according to a non-inferiority design, with the possibility to 
shift to superiority following current regulatory guidelines.12 13 
The trial was registered on the European Medicines Agency 
database accessible at www.clinicaltrialsregister.eu (EudraCt 
no 2008-003875-35). Ethics approval was provided by the eth-
ics review boards of the coordinating investigators (co-authors 
FB and JG) in France and Germany (Comité de Protection des 
Personnes, AP-HP St-Antoine Hospital, Paris and the ethics 
committee of Regensburg University, respectively) and by all 
applicable local ethics committees. After signing an informed 
consent, patients were screened at least 7 days before ran-
domisation. Patients received 3-weekly injections of the test or 
comparator preparations (1:1 allocation ratio) and were then 
seen at weeks 6, 14, 20 and 26, ie, 4, 12, 18 and 24 weeks fol-
lowing the end of treatment.
Patient selection
Patients of either sex, aged 50–80 years, fulﬁ lling the American 
College of Rheumatology clinical and radiological criteria for 
knee osteoarthritis,14 were enrolled if they had a history of 
symptoms for at least 6 months and insufﬁ cient/failed response 
to analgesics and/or regular non-steroidal anti-inﬂ ammatory 
drugs (NSAID), or were intolerant to regular NSAID or weak opi-
oids. Current symptoms (after ≥2 days wash-out from NSAID, 
including topical agents, or 1 day from non-narcotic analgesics) 
had to include global knee pain of 40 mm or greater on a 100 
mm visual analogue scale (VAS), Western Ontario and McMaster 
Universities (WOMAC) pain subscale score of 25 or greater on 
the 0–100 normalised scale and Lequesne index of 4 or greater. 
x-Rays (past 12 months) had to show Kellgren and Lawrence 
stage II or III; radiological evidence of bilateral knee osteoarthri-
tis was accepted if global pain VAS in the contralateral knee was 
less than 30 mm. Main exclusions were: isolated/predominantly 
patellofemoral symptomatic osteoarthritis, secondary knee 
osteoarthritis, symptomatic hip osteoarthritis homolateral to the 
target knee, inﬂ ammatory or other rheumatic diseases, clinical 
joint effusion, excessive (≥8°) varus or valgus knee deformity (at 
physical examination, as conﬁ rmed by standard radiograph).
Figure 1 Trial profi le.
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Treatments, randomisation, allocation concealment and blinding
GO-ON (Rottapharm|Madaus, Monza, Italy) is a preparation of 
sodium hyaluronate obtained by fermentation from Streptococcus 
equi, with an intermediate MW (range 800 000–1 500 000 
Daltons), presented in 2.5 ml preﬁ lled syringes and a concentra-
tion of 10 mg/ml. Hyalgan (Fidia Abano Terme, Italy) is sodium 
hyaluronate derived from rooster combs, with a low MW (range 
500 000–730 000) and a concentration of 10 mg/ml in 2 ml. Both 
preparations are recommended for cycles of 3–5-weekly injec-
tions, but studies have shown no apparent difference between 
the two regimens with Hyalgan.3 Treatments were therefore 
administered intra-articularly, using a lateral femoropatellar 
approach, at 3-weekly intervals.
A block randomisation list was computer-generated and elec-
tronically associated to a pack list (each pack containing one 
syringe) by independent groups who maintained their secrecy, 
having no contacts with the investigators or personnel involved 
in the conduct of the study. Blocks were balanced at each site 
and their size was secret to maintain blinding. Randomisation 
was centralised by an interactive voice response system: the ran-
domisation call assigned the ﬁ rst available position in the ran-
domisation list and therefore the ﬁ rst treatment pack (identiﬁ ed 
by a unique number) available at the site. Two additional calls 
were made to obtain the pack number for the second and third 
injections. Consequently, there was no possibility for the inves-
tigator to predict the next treatment assignment, thus ensuring 
adequate allocation concealment.
Given the impossibility of obtaining identical presentations 
of the compared medications, double-blind conditions were 
obtained by appointing at each site one ‘injector investigator’ 
in charge of independently administering the treatments and 
one ‘assessor investigator’ performing all assessments blinded to 
the treatment. Patient blinding was ensured by avoiding visual 
access to the injection ﬁ eld (eg, by a screen between the patient 
and his/her knee). Double-blind conditions were successfully 
achieved for all patients (as noted in the case record form).
Use of paracetamol up to 4 g per day for four consecutive days 
was allowed as rescue medication if unbearable pain had not 
improved after at least 1 h rest. In case of paracetamol failure or 
contraindication, NSAID could be prescribed for a limited and 
speciﬁ ed period. Paracetamol or NSAID had to be stopped 24 h 
or 2 days, respectively, before each assessment visit. Daily con-
sumption of the rescue medication was recorded in a patient 
diary. No other use of paracetamol or NSAID (excluding aspirin 
<325 mg/day as antiaggregant) was allowed during the study, 
similar to opioids, intra-articular or systemic corticosteroids 
(washout ≥1 and 3 months, respectively), or other HA prepa-
rations (washout ≥12 months). Glucosamine sulphate, other 
glucosamines or other slow-acting drugs for osteoarthritis (eg, 
chondroitin sulphate, diacerhein or avocado/soybean unsa-
poniﬁ ables) were allowed if at a stable dosage for 3 months or 
more.
Effi cacy outcomes
The pain subscale of the WOMAC osteoarthritis index (VAS 
version VA3.1) was the study primary endpoint.15 Results were 
normalised on a 0–100 scale for each domain, with the total 
index, physical function and stiffness subscales being assessed 
as secondary endpoints.
Other secondary efﬁ cacy endpoints included: global knee 
pain during the past 48 h on a 0–100 mm VAS; the Lequesne 
algofunctional index;16 the intermittent and constant osteoar-
thritis pain (ICOAP) index on the 0–100 score transformation 
recommended by the OARSI and outcome measures in rheuma-
tology (OMERACT);17 patient global assessment (PGA) on a 100 
mm VAS (see supplementary material 2, available online only, 
for the exact wording of this and the global knee pain VAS ques-
tion); the proportion of OARSI/OMERACT responders.18 The 
proportion of patients achieving the minimum clinically impor-
tant improvement (MCII) and patient acceptable symptom state 
(PASS)19 20 was also calculated for global pain VAS, WOMAC 
function subscale and PGA. Consumption of the rescue medica-
tion was another efﬁ cacy endpoint.
Safety assessment
The safety population comprised all patients receiving at least one 
injection of the study medication. Adverse events (AE) observed 
by the investigators or reported by the patients spontaneously or 
Table 1 Patient demographic and baseline characteristics in the 
ITT population
 GO-ON (n=217) Hyalgan (n=209)
Age (years)  67.2±7.8  66.1±8.1
Women, n (%) 135 (62%) 134 (64%)
BMI (kg/m2)  28.0±3.0  27.7±3.1
Kellgren and Lawrence, n (%)
Grade II 101 (46%) 113 (54%)
Grade III 116 (54%)  96 (46%)
WOMAC index scores (0–100 scale)
Pain subscale  47.5±14.3  48.8±14.9
Stiffness subscale  46.4±20.8  48.5±19.7
Function subscale  48.7±17.1  49.3±16.4
Total index  48.2±15.8  49.1±5.3
Global knee pain VAS (0–100 mm)  62.1±13.0  64.2±13.1
Lequesne index of severity (0–24 points)  11.2±2.9  11.2±3.0
PGA VAS (0–100 mm)  48.4±18.1  47.3±17.7
ICOAP total (0–100 scale)  46.4±16.7  48.2±17.4
ICOAP constant (0–100 scale)  43.2±18.4  44.8±19.6
ICOAP intermittent (0–100 scale)  49.2±17.0  51.0±17.3
Data are mean±SD unless otherwise indicated.
BMI, body mass index; ICOAP, index of intermittent and constant osteoarthritis pain; 
ITT, intention-to-treat; PGA, patient global assessment; VAS, visual analogue scale; 
WOMAC, Western Ontario and McMaster Universities.
Figure 2 Intention-to-treat mean (and SE) change from baseline at 
each assessment time point for the Western Ontario and McMaster 
Universities pain subscale score in the two groups receiving GO-ON 
(n=217) or Hyalgan (n=209). The arrows indicate the intra-articular 
injections.
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following a non-leading question, were coded using the Medical 
Dictionary for Regulatory Activities. Particular attention was 
paid to local painful reactions at the injection site, postinjection 
reactions (eg, effusions) and acute pseudoseptic arthritis.21
Statistical analysis
The primary outcome was the difference in the mean change 
from baseline on the WOMAC pain subscale score at week 26 
(6 months after the end of treatment). The acceptable margin 
for non-inferiority was preset at −9 mm, ie, less than the mini-
mum perceptible clinical improvement of −10 mm.22 GO-ON 
would be declared non-inferior to Hyalgan if the lower limit of 
the 95% CI lies above −9 mm in both the per-protocol (PP) and 
intention-to-treat (ITT) populations.12 13 If the 95% CI also lies 
above zero in ITT, there is evidence of superiority at the 5% 
signiﬁ cance level and a two-way analysis of variance (ANOVA) 
with treatment and study centre as factors provided the actual 
p value, with no multiplicity argument affecting this interpreta-
tion.12 13 The effect size was calculated according to Hedges.23
The sample size on this non-inferiority margin was calcu-
lated assuming a SD of 23 mm, based on a previous study with 
Hyalgan24 and conservatively increased by 15%, resulting in 144 
patients per group in the PP population to achieve a power of 
90% at a signiﬁ cance level of 5%. Assuming a 30% discontinua-
tion rate, this was increased to 200 patients per group in the ITT 
population, which consisted of all randomly assigned patients 
with at least one injection and one post-injection assessment of 
the primary endpoint.25 For drop-outs and other exclusions from 
the PP population, missing values were replaced by the base-
line value, according to the baseline observation carried-forward 
approach.26
All secondary endpoints were analysed for superiority, as pre-
determined in the protocol. The changes in the WOMAC total 
index and its subscales, global knee pain, Lequesne index, PGA, 
ICOAP index and daily mean rescue medication consumption 
were analysed by ANOVA as the primary endpoint. The propor-
tions of OARSI/OMERACT responders and patients with MCII 
or PASS were compared by the χ2 test, similar to the number of 
patients with AE and those using the rescue medication (worst 
case approach for drop-outs in the latter case). An analysis at 
week 14 (12 weeks after the end of treatment), was also per-
formed as exploratory on all parameters. Demographic and 
baseline characteristics were compared by two-way ANOVA 
for continuous variables or the Cochran–Mantel–Haenszel 
test, controlling for study centre, for categorical parameters. 
Statistical analyses were performed using the SPSS statistical 
package (version 9.2).
RESULTS
Patient disposition is described in ﬁ gure 1. The ﬁ rst patient was 
enrolled in November 2008 and the last patient was completed 
in November 2009. Out of 437 patients randomly assigned, 217 
and 209 in the GO-ON and Hyalgan groups, respectively, were 
included in the ITT population, thus excluding only 11 patients 
according to the predeﬁ ned criteria. Protocol violations were the 
main reason for exclusion from the PP population, and consisted 
mainly of failure to meet the inclusion/exclusion criteria or use 
of prohibited medications. Less than 10% of patients were 
withdrawn for other reasons (AE, treatment failure, withdrawal 
of consent, other). All withdrawals/exclusions were similarly 
distributed between groups.
Table 1 shows the demographic and baseline characteristics 
of the ITT population, without differences between groups 
and well representative of the common knee osteoarthritis out-
patient population: mostly women (63%), mean age approxi-
mately 67 years, moderately overweight (average body mass 
index approximately 28) and with Kellgren and Lawrence radio-
logical grades II and III evenly distributed. Knee osteoarthritis 
symptoms were moderate to severe, with average pain and 
function scores in the middle of their scales, pain VAS of the sig-
nal knee greater than 60 mm and Lequesne index approximately 
11 points. There were no differences between the ITT and PP 
baseline populations (data not shown).
The ITT changes from baseline in the WOMAC pain subscale 
are reported in ﬁ gure 2. Patients in both groups improved mark-
edly during the ﬁ rst month after treatment and the effect was 
maintained for the duration of the study, with GO-ON exhibiting 
an overall better trend, that was particularly consistent between 
12 and 24 weeks after the end of treatment. After 6 months from 
the end of treatment (ie, week 26), patients who had received 
GO-ON had decreased their WOMAC pain score by 22.9±1.4 
mm (mean±SE), compared with 18.4±1.5 mm with Hyalgan in 
the ITT population. The primary analysis was ﬁ rst conducted on 
the PP population according to the non-inferiority study design 
and then on the ITT population. The changes from baseline and 
their 95% CI are reported in ﬁ gure 3; as in both PP and ITT the 
lower limit of the 95% CI was higher than the predeﬁ ned mar-
gin of −9 mm, this allowed us to conclude to the treatment non-
inferiority. Furthermore, as this lower limit was above 0, the ITT 
analysis also allowed us to conclude to the statistical superiority 
of GO-ON versus Hyalgan (p=0.021) (ﬁ gures 2 and 3, table 2), 
with an effect size of 0.21. This result did not change in a sensi-
tivity analysis including the 11 patients excluded from the ITT 
population, according to a stricter ITT approach accounting for 
all randomly assigned patients (p=0.026).
Figure 3 Point estimate and 95% CI of the difference (GO-ON vs Hyalgan, in mm) in the primary outcome represented by the Western Ontario and 
McMaster Universities pain subscale mean improvement. Values are differences in mean changes between GO-ON and Hyalgan at 6 months after 
treatment in the per-protocol (PP) and intention-to-treat (ITT) populations (−9 mm was the non-inferiority margin).
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Table 2 shows this superiority pattern for the majority of 
the secondary endpoints. Global knee pain VAS decreased by 
over 50% with GO-ON at week 26, but less with Hyalgan 
(effect size 0.26). A similar degree of efﬁ cacy was detected for 
all WOMAC scales and the Lequesne index underwent an over 
4-point decrease with GO-ON versus 3 points with Hyalgan 
(effect size 0.34). The degree of improvement was similar 
for the ICOAP index, but the difference between groups was 
barely signiﬁ cant only for constant pain, while the two prepa-
rations behaved similarly on intermittent pain. Patients had 
also improved their global assessment VAS by almost 20 mm 
with GO-ON, but the better trend versus Hyalgan was not sig-
niﬁ cant in ITT (p=0.068, table 2), but only in the PP analysis 
(p=0.044, data not shown).
Table 2 also shows that there were 73% OARSI/OMERACT 
responders 6 months after the end of treatment with GO-ON, 
versus 58% with Hyalgan (difference 14.9%, p=0.001). The 
proportion of patients achieving MCII and PASS for global knee 
pain, function and PGA was also high with both treatments but 
signiﬁ cantly higher with GO-ON than with Hyalgan except for 
global pain PASS and MCII for PGA (table 2).
All superiority trends were similar at the 12-week endpoint 
(data not shown), with a signiﬁ cant difference in the proportion 
of OARSI/OMERACT responders, 69.6% with GO-ON versus 
60.3% with Hyalgan (p=0.044).
Patients used the rescue medication in a similar proportion: 
166 out of 217 on GO-ON (77%) and 154 out of 209 (74%) with 
Hyalgan (p=0.50), with a low paracetamol daily mean consump-
tion (218 and 223 mg/day, respectively, p=0.60); see supplemen-
tary text 3 (available online only).
The treatments were well tolerated. The proportion of patients 
reporting any AE in the safety population was similar: 74 out 
of 223 (33.2%) and 75 out of 213 (35.2%) with GO-ON and 
Hyalgan, respectively, most AE being unrelated to treatment. 
Back pain was the only AE reported with greater than 3% inci-
dence. AE led to study discontinuation for three patients under 
GO-ON (worsening of knee osteoarthritis in two patients, only 
one of which was considered possibly related to the treatment, 
and one metastatic pulmonary cancer) and four patients under 
Hyalgan (worsening of knee osteoarthritis, post-traumatic 
meniscal lesion, ischaemic stroke, angiosarcoma with pleu-
ral effusion). Local AE are reported in table 3; both treatments 
were well tolerated locally. Although not statistically signiﬁ cant 
(p=0.17), the proportion of patients reporting local AE was dou-
ble with Hyalgan (3.8%) compared with GO-ON (1.8%). No 
case of acute pseudoseptic arthritis was observed.
DISCUSSION
In the present randomised, double-blind, controlled trial in over 
400 knee osteoarthritis patients, three-weekly HA intra-articular 
injections decreased moderate to severe pain after 6 months by 
up to 50% of baseline values. Joint function improved to a simi-
lar extent and there were over 65% treatment responders on 
average with the two preparations used. The intermediate MW 
HA formulation GO-ON was not inferior to the reference low 
MW preparation Hyalgan on the WOMAC pain subscale score, 
but was also statistically superior on this primary and on most 
of the secondary outcomes as predetermined by the statistical 
analysis plan.12 13
While GO-ON tended to exhibit a trend for a better pattern of 
response throughout the study, both treatments behaved simi-
larly well over the ﬁ rst month, when most of the therapeutic 
gain was observed, and during the ﬁ rst 3 months following the 
injection course. Afterwards, the beneﬁ t obtained with the low 
MW product tended to plateau, as acknowledged with most HA 
preparations,9 while there was a slight continuous improvement 
with GO-ON, ie, a more pronounced carry-over effect resulting 
in a statistically signiﬁ cant superiority on most outcomes after 
6 months.
The primary endpoint was the change from baseline in the 
WOMAC pain subscale score, which displayed an extent of 
improvement similar to global knee pain VAS. The statistically 
signiﬁ cant ITT differences between treatments after 6 months 
were 4.5 and 6.4 mm, respectively, ie, below the minimum 
perceptible clinical improvement, usually set at approximately 
10 mm22 and that was used to deﬁ ne the non-inferiority margin 
Table 2 Mean changes (and 95% CI) from baseline to the endpoint (week 26, ie, 6 months after the end of treatment) in the ITT population for 
primary (WOMAC pain subscale) and secondary outcomes, including number (and percentages) of OARSI/OMERACT responders and of patients 
achieving MCII and PASS, with difference between groups and p value
 GO-ON (n=217) Hyalgan (n=209) Difference p Value Effect size*
WOMAC pain −22.9 (−25. 7 to −20.1) −18.4 (−21.3 to −15.5) −4.5 (−8.5 to −0.5) 0.021 0.21 (0.02 to 0.40)
WOMAC function −22.2 (−25.1 to −19.3) −15.4 (−18.2 to −12.7) −6.8 (−10.7 to −2.8) 0.0004 0.32 (0.13 to 0.52)
WOMAC stiffness −21.0 (−24.3 to −17.7) −15.7 (−19.0 to −12.4) −5.3 (−10.0 to −0.6) 0.027 0.22 (0.02 to 0.41)
WOMAC total −22.2 (−25.0 to −19.4) −16.1 (−18.8 to −13.4) −6.2 (−10.0 to −2.3) 0.001 0.31 (0.11 to 0.50)
VAS pain −33.2 (−36.5 to −29.8) −26.7 (−30.0 to −23.4) −6.4 (−11.1 to −1.8) 0.004 0.26 (0.07 to 0.45)
Lequesne index −4.2 (−4.7 to −3.7) −3.0 (−3.5 to −2.5) −1.2 (−2.0 to −0.6) 0.0002 0.34 (0.15 to 0.53)
ICOAP total −21.0 (−23.8 to −18.3) −17.9 (−20.8 to −15.1) −3.2 (−7.0 to 0.9) 0.13 –
ICOAP constant −21.3 (−24.4 to −18.3) −16.9 (−19.8 to −14.0) −4.5 (−8.6 to 0.3) 0.052 –
ICOAP intermittent −20.8 (−23.6 to −18.0) −18.8 (−21.9 to −15.8) −1.9 (−6.0 to 2.2) 0.32 –
VAS patient global    18.8 (15.1 to 22.5)    14.3 (10.6 to 17.9)    4.6 (−0.6 to 9.8) 0.068 –
OARSI/OMERACT responders, n (%)    159 (73.3%)    122 (58.4%)    37 (14.9%) 0.001 –
MCII pain, n (%)    153 (70.5%)    122 (58.4%)    31 (12.1%) 0.009 –
PASS pain, n (%)    125 (57.6%)    102 (48.8%)    23 (8.8%) 0.069 –
MCII function, n (%)    150 (69.1%)    117 (56.0%)    33 (13.1%) 0.005 –
PASS function, n (%)    137 (63.1%)    97 (46.4%)    40 (16.7%) 0.0005 –
MCII patient global, n (%)    113 (52.1%)    92 (44.0%)    21 (8.1%) 0.096 –
PASS patient global, n (%)    126 (58.1%)    90 (43.1%)    36 (15.0%) 0.002 –
All indices and scores are on a natural 0–100 mm or normalised 0–100 scale, except the Lequesne index. Baseline values are reported in table 1.
*Effect size and 95% CI shown only for continuous variables and where p<0.05.
ICOAP, index of intermittent and constant osteoarthritis pain; ITT, intention-to-treat; MCII, minimum clinically important improvement; OARSI, Osteoarthritis Research Society 
International; OMERACT, outcome measures in rheumatology; PASS, patient acceptable symptom state; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster 
Universities.
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of 9 mm in this trial. Therefore, the clinical relevance of this 
statistical superiority is uncertain and it cannot be excluded that 
it is due to chance. However, the effect size ranged between 
0.21 and 0.26 for the two pain endpoints, representing a small 
albeit clinically relevant difference. Moreover, there was a sig-
niﬁ cantly higher proportion of OARSI/OMERACT responders 
after 6 months with GO-ON (73%) than with Hyalgan (58%), 
ie, a 15% difference that is beyond the accepted minimum 
clinically relevant improvement. The OARSI/OMERACT crite-
ria require high improvement in pain or function (≥50% with 
absolute 0–100 change ≥20), or a moderate improvement (≥20% 
with ≥10 absolute change) in two out of pain, function or PGA, 
thus representing a real clinical improvement.18 Notably, there 
were signiﬁ cantly more OARSI/OMERACT responders with 
GO-ON already at the 12-week endpoint, as a prelude to the 
better carry-over effect that was then fully substantiated after 
6 months. Similar proportions and differences in response 
rates were observed for patients reaching the MCII19 on pain 
and function after 6 months. Moreover, approximately 60% of 
patients achieved a PASS20 with GO-ON, with a signiﬁ cant dif-
ference compared with Hyalgan for function, but not for pain. 
PGA provided a slightly lower degree of improvement, without 
differences between treatments in absolute terms and as MCII, 
but with a more than 15% signiﬁ cantly higher proportion of 
patients reaching PASS with GO-ON.
A favourable feature of the present trial is that it assessed 
knee osteoarthritis symptoms through several different mea-
sures, providing a complete evaluation. Beside all WOMAC 
subscales showing a signiﬁ cant advantage for the intermediate 
MW product, the Lequesne index resulted in an effect size of 
0.36 in favour of GO-ON. In addition, pain was also assessed 
by the new ICOAP index;17 interestingly, patients had slightly 
more severe baseline values for ‘intermittent’ pain, in which the 
two treatments displayed a similar efﬁ cacy, while GO-ON was 
better than Hyalgan on the slightly less severe ‘constant’ pain.
This study also has some limitations. First, there was no pla-
cebo comparison. This might have been an issue in the case of 
results limited to non-inferiority, given the debated efﬁ cacy of 
HA in general.9 However, as GO-ON was statistically superior 
to the low MW product and most of the differences were clini-
cally relevant, this might represent sufﬁ cient evidence of efﬁ -
cacy. Moreover, ethics review boards might have raised ethical 
concerns in using intra-articular saline as a placebo when HA 
injections are now widely prescribed in knee osteoarthritis.
Second, it was not possible to provide identically appearing 
test and comparator preparations: the commercial preparations 
had to be used for obvious reasons, after appropriate packaging, 
and their effects may also differ given the different injected vol-
umes. On the other hand, double-blind conditions were ensured 
by nominating at each site an ‘injector’ and a blinded ‘assessor’ 
investigator, while avoiding the patient’s visual access to the 
injection ﬁ eld. Despite these difﬁ culties, which are standard 
practice in these kind of trials, there was no evidence of broken 
double-blindness for any patient, reinforced by the strict assur-
ance of adequately concealed random allocation by the interac-
tive voice response system.
Third, this was a regulatory trial that was therefore industry-
funded. Compared with non-industry-funded trials, sponsored 
studies more often yield results in support of the sponsor’s 
drug.27 To avoid any potential allegations, an independent steer-
ing committee (FB, XC, FR, EM) supervised the trial design and 
study conduct, participated in blind data review meetings before 
database lock and provided binding recommendations for data 
management, ﬁ nally accessing all results.
A fourth limitation was that the present trial only compared 
the intermediate HA product GO-ON with the reference low 
MW preparation, but not with a higher MW, cross-linked, for-
mulation. While former studies suggested that high MW HA 
might have greater efﬁ cacy,4 in a recent meta-analysis11 show-
ing that HA has more prolonged efﬁ cacy than intra-articular cor-
ticosteroids in knee osteoarthritis, ﬁ ve of the seven considered 
studies (and the only two high-quality trials) were performed 
with the low MW HA product used as reference in the pres-
ent trial. Corticosteroids had a superior analgesic effect over the 
ﬁ rst 2 weeks, as expected, but from 8 weeks onwards and in 
particular 6 months after treatment HA had better pain control, 
with an effect size up to 0.39. Another meta-analysis10 found 
no evidence of a clinically relevant beneﬁ t of hylan compared 
with lower MW HA preparations, and a recent trial concluded 
to the non-inferiority between another intermediate MW HA 
and hylan G-F20.28 Actually, a study of single intra-articular 
hylan injection showed only a modest, albeit signiﬁ cant, beneﬁ t 
versus placebo over 6 months on knee pain, with less OARSI/
OMERACT responders than with GO-ON in the present trial 
and a non-signiﬁ cant difference with placebo.29
A recent study has shown that low MW (50 000 Daltons) HA 
may have pro-inﬂ ammatory activity on chondrocytes, while 
intermediate MW preparations were neutral in this model of 
inﬂ ammation.30 It is difﬁ cult to transpose in-vitro results to 
humans and to the actual preparations used here, but this may 
partly explain the efﬁ cacy results of the present study, with 
good safety at the injection site compared with even higher MW 
products. Indeed, while in a recent trial hylan showed only a 
trend towards a higher incidence of local adverse reactions com-
pared with placebo,29 previous studies suggested a doubling risk 
of local AE with the high MW HA preparation compared with 
lower MW products,10 which may be due to peptide contami-
nants, formaldehyde, or crystal-induced inﬂ ammation. In the 
present study, GO-ON and Hyalgan were equally well tolerated 
at the injection site, although numerically more local reactions 
occurred with Hyalgan than with GO-ON, therefore showing a 
very good safety of the latter.
In conclusion, this trial shows that the intermediate MW HA 
preparation GO-ON is effective on knee osteoarthritis symp-
toms over 6 months after a 3-weekly injection course, and may 
be more effective than the reference low MW formulation. 
Further studies are warranted to elucidate the mechanism of this 
possible superiority and more pronounced carry-over effect and 
to test whether this selected HA preparation has a prominent 
therapeutic proﬁ le compared with other HA products.
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